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Abstrak
Latar belakang: Infeksi virus Infl uenza A dapat menyebabkan wabah di seluruh dunia. Wabah virus H1N1 
terjadi di Indonesia pada bulan April 2009. Sebanyak 1892 kasus terduga H1N1 dilaporkan antara April 
dan akhir Desember 2009. Dari 1892 kasus yang terduga, hanya 809 dikonfi rmasi terinfeksi virus H1N1. 
Karena virus strain baru, maka perlu diketahui persentase kasus yang mengembangkan antibodi anti 
H1N1 setelah infeksi pertama kali.
Metode: Penelitian menggunakan sera yang disimpan dari yang dikumpulkan pada tahun 2009 yang 
disimpan pada-70o C di laboratorium virologi di Lembaga Penelitian dan Pengembangan Kesehatan. 
Ujia yang digunakan ialah uji HI untuk menentukan kekebalan setelah infeksi Infl uenza A/H1N1pdm09. 
Hasil: Hanya sebagian kecil kasus terinfeksi fl u A/H1N1pdm09 selama wabah mengembangkan antibodi 
pelindung anti H1N1pdm09. Dari 205 sera yang diperiksa, 38 kasus (18,5%) mengembangkan antibodi 
anti H1N1pdm09 dengan HI titer ≥ 1:40. 
Kesimpulan: Sebanyak 18,5% kasus yang mengembangkan antibodi anti H1N1pdm09 di antara kasus 
terinfeksi fl u A/H1N1pdm09 selama wabah 2009. (Health Science Indones 2013;1:37-40)
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Abstract
Background: Infl uenza A virus infection can cause pandemic infl uenza worldwide. The outbreak of the H1N1 
virus occurred in Indonesia in April 2009. A total of 1892 suspected cases of H1N1 were reported between 
April and the end of December 2009. From 1892 suspected cases, there were only 809 confi rmed infected by 
the H1N1 virus. Since the virus is a new strain, we wanted to know how many cases developed antibody anti 
H1N1 after the fi rst infection occurred.
Methods: We used archived sera which was collected in 2009 and stored at -70oC in the virology laboratory of 
the National Institute of Health Research and Development. We used the HI assay to determine the immunity 
after infection of Infl uenza A/H1N1pdm09 in 2009. 
Results: Only a small proportion of cases infected during an outbreak of fl u A/H1N1pdm09 develop protective 
antibodies anti H1N1pdm09. Of 205 sera were examined, 38 cases (18.5%) developed anti H1N1pdm09 with 
HI antibody titer ≥ 1:40.
Conclusion: A total of 18.5% of cases develop antibodies anti H1N1pdm09 among A/H1N1pdm09 fl u cases 
during the 2009 outbreak. (Health Science Indones 2013;1:37-40)
Keywords: Infl uenza, antibody, pandemic, 2009 
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Laboratory-based infl uenza detection is a system that 
detects symptomatic patients who seek medical advice 
and are then appropriately tested and case notifi cations 
sent. Measurement of antibodies against infl uenza A 
(H1N1pdm09) can be used to assess the spread of 
population exposure to the virus. The infl uenza A 
(H1N1pdm09) is a disease caused by the infl uenza 
virus belonging to the family Orthomyxoviridae. 
Infl uenza viruses can be divided into three types or 
genera; A, B and C. Furthermore, infl uenza virus 
type A can be divided into many different subtypes 
based on surface antigens: hemagglutinin (HA) and 
Neuraminidase (NA). Until now there are found 
16 subtypes of HA and 9 NA subtypes.1 In addition 
to seasonal infl uenza A (H3N2) and infl uenza A 
(H1Npdm09) virus epidemics, from time to time new 
infl uenza A viruses from animal origin are introduced in 
the human population. When these new viruses are able 
to spread effi ciently among humans, they can cause an 
infl uenza virus outbreak since almost all people do not 
have antibodies against this new virus strains.2
In the early 21st century,  a new strain of infl uenza A 
(H1N1) virus emerged causing an outbreak in the human 
population. This virus was originally detected in the in 
Mexico and the United State in March and early April 
2009. In June 11, 2009, the World Health Organization 
announced that the Vigilance Outbreak  Infl uenza 
has reached the highest phase (phase 6).3,4 Almost all 
countries affected by  the Infl uenza A (H1N1pdm09) 
virus, including Indonesia, became epidemic and 
according to the infl uenza virus nomenclature, this novel 
H1N1 strain was named Infl uenza A (H1N1pdm09).  
The Garten study results indicate that there are 
dissimilarities between infl uenza virus A/H1N1pdm09 
2009 with the H1N1 infl uenza virus that circulated 
earlier.5 The previous study found that the antigenic 
characteristics of the infl uenza A (H1N1pdm09) 
virus circulating in Indonesia matched the A/
California/07/2009 strain.6 
A total of 1892 suspected cases of infl uenza A 
(H1N1pdm09) were reported between April 2009 
and the end of December 2009 in Indonesia. The 
confi rmation examination conducted at the Center for 
Biomedical and Basic Technology of Health was done 
with realtime RT-PCR according to WHO guidelines 
using throat and nasal swabs. 890 out of 1892 
suspected cases were confi rmed positive for infection 
by Infl uenza A (H1N1pdm09). Twelve of these cases 
were fatal. On August 10, 2012, WHO declared that 
during the outbreak of Infl uenza A (H1N1pdm09) 
206 countries reported laboratory confi rmation of the 
Infl uenza A (H1N1pdm09).4
Since it was a very short time that the outbreak 
occurred, we wondered about the development of 
antibody anti infl uenza A (H1N1pdm09) among 
the human cases in Indonesia. This study aimed 
to determine the immunity status of the confi rmed 
cases after the fi rst infection occurred by detection of 
antibody anti infl uenza A (H1N1pdm09).
METHODS
Samples collection 
During the outbreak  of Infl uenza A (H1N1pdm09) 
in Indonesia, beginning in April 2009, all specimens 
such as throat and nasal swabs and sera were sent 
from many hospitals in Indonesia to the Virology 
Laboratory, National Institute of Health Research 
and Development as the reference laboratory in 
Indonesia. Patient swabs were tested by realtime RT-
PCR for infl uenza A (H1N1pdm09) detection, and 
the sera was stored in the deep freezer until used 
for the further examination. A total of 205 archived 
sera out of 890 confi rmed infl uenza A (H1N1pdm09) 
cases were tested in this study.
Laboratory examination
To determine the antibody anti H1N1, we used 
Hemagglutination Inhibition assay (HI) and infl uenza 
A (H1N1pdm09) with A/California/07/2009 strain 
used as the antigen against the sera. A total of 20 ul of 
serum was incubated with 60 ul respirator destroying 
enzyme (RDE) at 370 C overnight. Then using V 96 
well plate, 50 ul Phosphate Buffer Saline was put 
in each well. 50 ul of serum was incubated with 
RDE in the fi rst well. Two-fold serial dilutions were 
performed, and 50 ul infl uenza A (H1N1pdm09) 
antigen was added to all wells and incubated for 1 
hour. 0.5% turkey red blood cells were added lastly.7 
Titer ≥ 1:40 is considered as a positive antibody 
anti infl uenza A (H1N1pdm09.8
RESULTS
Table 1 showed that there was variation in the 
antibody titer against the antigen A/H1N1pdm09. 
Among the 205 sera examined, 50 cases showed 
antibody anti infl uenza A (H1N1pdm09) with an 
antibody titer range from ≤ 10 to 640. Most of the 
cases (75.6%) had low titers. Negative (titers of 
≤ 1:20) antigen infl uenza A (H1N1pdm09) were 
81.5%. Therefore, those who had positive antigen 
infl uenza A (H1N1pdm09) were 18.5%.
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Table 1.  The results of antibody titers against the 
antigen infl uenza A (H1N1pdm09)
Antibody anti 
infl uenza A Titer Cases (n=205)
n % Sub total
Negative < 10 155 75.6 81.5
20 12 5.9
Positive 40 12 5.9 18.5
80 13 6.3
160 6 2.9
320 1 0.5
640 6 2.9
DISCUSSIONS 
Infl uenza A (H1N1pdm09) outbreak occurred in 
almost all countries in the year 2009. It was a tough 
challenge for the implementation of the surveillance 
system and quick handling of the case. By this 
antibody detection, the degree of immunity from 
infl uenza A (H1N1pdm09) cases is known. The data 
of the Hemagglutination Inhibition (HI) assay could 
be analyzed more completely, if the results were 
associated by the age of patient, history of disease, 
vaccination records and geographic data similar to 
the study which had been done in Shandong, China. 
The results of  their seropositive rate for infl uenza A 
(H1N1pdm09) antibodies was 25,9% with most cases 
detected in the 0-5 years age range group and also in 
the elderly group aged ≥ 60 year old.8 Similar fi ndings 
were made in Italy.   The highest number of cases with 
an antibody response for infl uenza A (H1N1pdm09) 
were children with a hospitalized history.10 
Referring to the results of this study, clearly elaborate 
antibody response in the infl uenza A (H1N1pdm09) 
cases, a seropositive rate of 18.6% was observed. If 
this result is compared with the seropositive rate in 
the U.S. which was 20.2%, it means that the incidence 
of cases in Indonesia with infl uenza A (H1N1pdm09) 
was almost the same as the incidence of cases in 
America.9 In the other countries in the southern 
hemisphere, such as Australia, New Zealand and 
Singapore, the post outbreak seropositivity proportion 
was 17.5% in Singapore. Australia and NZ ranged 
from 22.1% to 32.8%. The seropositivity in Indonesia 
is consistent with Singapore as tropical regions show 
lower seropositivity compared with subtropical regions. 
These fi ndings might be explained that the transmission 
of infl uenza increased in cold temperatures.11
Immunity cases in Indonesia infl uenza A (H1N1pdm09) 
formed after infection or may have come from previous 
exposure to infl uenza A (H1N1pdm09). Furthermore, 
not all cases directly produce antibodies after infection. 
However, this study has limitations. First, serum 
samples used had been stored since 2009 and had been 
examined in 2011. So, there is the possibility of antibody 
levels having decreased due to storage time. Second, 
all the samples came from an outbreak infl uenza A 
(H1N1pdm09), and there was limited data and records 
on the patents. Therefore, the immune status against 
infl uenza A (H1N1pdm09) cannot be analyzed since 
we did not have the baseline data and the test results 
could not be linked with the disease incubation period 
of the patients. Third, there was limited serum for the 
seroconversions since there was no follow up of the 
patients after they recovered from the illness and left 
the hospitals. The seroconversions levels are important 
to show the immunology status of the patients.  Fourth, 
according to laboratory tests, HI assay is not the most 
sensitive examination for detecting antibodies. It needs 
further laboratory tests with more sensitive detection 
such as the neutralization assay. 
Conclusions
A total of 18.5% of cases develop antibodies anti 
H1N1pdm09 among A/H1N1pdm09 fl u cases during 
the 2009 outbreak.
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